# Unity Biotechnology

its lead senolytic, UBX1325 (a Bcl-xL inhibitor), has produced 36-week clinical results and a NEJM Evidence publication supporting long-term vision improvement in diabetic macular edema and retinal disease.

Source: https://en.bioecon.ru/companies/unity-biotechnology/
Updated: 2026-07-03

- Country: United States
- Ticker: UBX

## Technologies

- [Geroscience & senolytics](https://en.bioecon.ru/technology/geroscience-senolytics/)